News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
500,410 Results
Type
Article (36792)
Company Profile (156)
Press Release (463462)
Section
Business (149944)
Career Advice (1541)
Deals (28879)
Drug Delivery (101)
Drug Development (69588)
Employer Resources (125)
FDA (11765)
Job Trends (11321)
News (267467)
Policy (29387)
Tag
Academia (1944)
Alliances (46473)
Alzheimer's disease (1116)
Approvals (11729)
Artificial intelligence (133)
Bankruptcy (268)
Best Places to Work (8823)
Breast cancer (160)
Cancer (1222)
Cardiovascular disease (97)
Career advice (1294)
Cell therapy (237)
Clinical research (55865)
Collaboration (521)
Compensation (263)
COVID-19 (2504)
C-suite (104)
Data (1150)
Diabetes (168)
Diagnostics (3948)
Drug pricing (96)
Earnings (54119)
Employer resources (113)
Events (66550)
Executive appointments (353)
FDA (12380)
Funding (370)
Gene therapy (188)
GLP-1 (661)
Government (4231)
Healthcare (12491)
Infectious disease (2601)
Inflammatory bowel disease (92)
Interviews (265)
IPO (12317)
Job creations (2898)
Job search strategy (1124)
Layoffs (328)
Legal (7795)
Lung cancer (180)
Lymphoma (90)
Manufacturing (201)
Medical device (6469)
Medtech (6472)
Mergers & acquisitions (16801)
Metabolic disorders (477)
Neuroscience (1421)
NextGen: Class of 2025 (4268)
Non-profit (2977)
Northern California (1350)
Obesity (283)
Opinion (205)
Parkinson's disease (89)
Patents (116)
People (40510)
Phase I (16635)
Phase II (24362)
Phase III (19385)
Pipeline (515)
Postmarket research (2232)
Preclinical (6956)
Radiopharmaceuticals (228)
Rare diseases (226)
Real estate (4075)
Regulatory (18817)
Research institute (1802)
Resumes & cover letters (226)
Southern California (1140)
Startups (2646)
United States (11598)
Vaccines (623)
Weight loss (226)
Date
Today (93)
Last 7 days (297)
Last 30 days (1484)
Last 365 days (26158)
2025 (1285)
2024 (26458)
2023 (29744)
2022 (39221)
2021 (42077)
2020 (40258)
2019 (33348)
2018 (25549)
2017 (25253)
2016 (24090)
2015 (27823)
2014 (22008)
2013 (18296)
2012 (19516)
2011 (20307)
2010 (18643)
Location
Africa (689)
Arizona (102)
Asia (33351)
Australia (5343)
California (2985)
Canada (1211)
China (302)
Colorado (137)
Connecticut (138)
Europe (73800)
Florida (444)
Georgia (93)
Illinois (285)
Indiana (177)
Maryland (560)
Massachusetts (2293)
Michigan (98)
Minnesota (141)
New Jersey (929)
New York (887)
North Carolina (559)
Northern California (1350)
Ohio (104)
Pennsylvania (689)
South America (995)
Southern California (1140)
Texas (384)
Washington State (275)
500,410 Results for "santhera pharmaceuticals ag".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Santhera Pharmaceuticals Provides Update on Royalty Agreement for AGAMREE® (Vamorolone) and Warrants held by Idorsia
January 16, 2025
·
6 min read
Press Releases
Santhera Enters into Supply and Distribution Agreement for AGAMREE® (Vamorolone) with Clinigen Group
January 6, 2025
·
5 min read
Press Releases
Santhera Receives Positive NICE Final Guidance for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
January 16, 2025
·
4 min read
Santhera’s Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States
Santhera Pharmaceuticals is pleased to note the launch of AGAMREE® for the treatment of Duchenne muscular dystrophy in the United States by Catalyst Pharmaceuticals, Inc., the Company’s commercialization partner for North America.
March 14, 2024
·
5 min read
Press Releases
Santhera Announces Approval in Hong Kong for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
December 20, 2024
·
5 min read
Press Releases
Santhera Receives Positive Recommendation from Scottish Medicines Consortium for the Use of AGAMREE® (Vamorolone) in Duchenne Muscular Dystrophy Patients in NHS Scotland
January 14, 2025
·
4 min read
Press Releases
Santhera Receives Positive Recommendation from NICE for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
December 10, 2024
·
6 min read
Press Releases
Santhera Announces Approval from China’s NMPA for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
December 11, 2024
·
6 min read
Business
Santhera Publishes Annual Report 2023
Santhera Pharmaceuticals announces the publication of its Annual Report 2023 with fully audited results for the year ended December 31, 2023.
May 28, 2024
·
2 min read
Policy
Santhera Publishes Agenda for its Annual General Meeting 2024
Santhera Pharmaceuticals published the invitation to its Annual General Meeting, which will be held on June 18, 2024, at 10:00 CEST at Haus der Wirtschaft, Hardstrasse 1, 4133 Pratteln, Switzerland.
May 28, 2024
·
2 min read
1 of 50,041
Next
